Cargando…

MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours

BACKGROUND: MYC is amplified in approximately 15% of breast cancers (BCs) and is associated with poor outcome. c-MYC protein is multi-faceted and participates in many aspects of cellular function and is linked with therapeutic response in BCs. We hypothesised that the functional role of c-MYC differ...

Descripción completa

Detalles Bibliográficos
Autores principales: Green, Andrew R, Aleskandarany, Mohammed A, Agarwal, Devika, Elsheikh, Somaia, Nolan, Christopher C, Diez-Rodriguez, Maria, Macmillan, R Douglas, Ball, Graham R, Caldas, Carlos, Madhusudan, Srinivasan, Ellis, Ian O, Rakha, Emad A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4984797/
https://www.ncbi.nlm.nih.gov/pubmed/26954716
http://dx.doi.org/10.1038/bjc.2016.46
_version_ 1782447991152443392
author Green, Andrew R
Aleskandarany, Mohammed A
Agarwal, Devika
Elsheikh, Somaia
Nolan, Christopher C
Diez-Rodriguez, Maria
Macmillan, R Douglas
Ball, Graham R
Caldas, Carlos
Madhusudan, Srinivasan
Ellis, Ian O
Rakha, Emad A
author_facet Green, Andrew R
Aleskandarany, Mohammed A
Agarwal, Devika
Elsheikh, Somaia
Nolan, Christopher C
Diez-Rodriguez, Maria
Macmillan, R Douglas
Ball, Graham R
Caldas, Carlos
Madhusudan, Srinivasan
Ellis, Ian O
Rakha, Emad A
author_sort Green, Andrew R
collection PubMed
description BACKGROUND: MYC is amplified in approximately 15% of breast cancers (BCs) and is associated with poor outcome. c-MYC protein is multi-faceted and participates in many aspects of cellular function and is linked with therapeutic response in BCs. We hypothesised that the functional role of c-MYC differs between molecular subtypes of BCs. METHODS: We therefore investigated the correlation between c-MYC protein expression and other proteins involved in different cellular functions together with clinicopathological parameters, patients' outcome and treatments in a large early-stage molecularly characterised series of primary invasive BCs (n=1106) using immunuohistochemistry. The METABRIC BC cohort (n=1980) was evaluated for MYC mRNA expression and a systems biology approach utilised to identify genes associated with MYC in the different BC molecular subtypes. RESULTS: High MYC and c-MYC expression was significantly associated with poor prognostic factors, including grade and basal-like BCs. In luminal A tumours, c-MYC was associated with ATM (P=0.005), Cyclin B1 (P=0.002), PIK3CA (P=0.009) and Ki67 (P<0.001). In contrast, in basal-like tumours, c-MYC showed positive association with Cyclin E (P=0.003) and p16 (P=0.042) expression only. c-MYC was an independent predictor of a shorter distant metastases-free survival in luminal A LN+ tumours treated with endocrine therapy (ET; P=0.013). In luminal tumours treated with ET, MYC mRNA expression was associated with BC-specific survival (P=0.001). In ER-positive tumours, MYC was associated with expression of translational genes while in ER-negative tumours it was associated with upregulation of glucose metabolism genes. CONCLUSIONS: c-MYC function is associated with specific molecular subtypes of BCs and its overexpression confers resistance to ET. The diverse mechanisms of c-MYC function in the different molecular classes of BCs warrants further investigation particularly as potential therapeutic targets.
format Online
Article
Text
id pubmed-4984797
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-49847972017-04-12 MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours Green, Andrew R Aleskandarany, Mohammed A Agarwal, Devika Elsheikh, Somaia Nolan, Christopher C Diez-Rodriguez, Maria Macmillan, R Douglas Ball, Graham R Caldas, Carlos Madhusudan, Srinivasan Ellis, Ian O Rakha, Emad A Br J Cancer Molecular Diagnostics BACKGROUND: MYC is amplified in approximately 15% of breast cancers (BCs) and is associated with poor outcome. c-MYC protein is multi-faceted and participates in many aspects of cellular function and is linked with therapeutic response in BCs. We hypothesised that the functional role of c-MYC differs between molecular subtypes of BCs. METHODS: We therefore investigated the correlation between c-MYC protein expression and other proteins involved in different cellular functions together with clinicopathological parameters, patients' outcome and treatments in a large early-stage molecularly characterised series of primary invasive BCs (n=1106) using immunuohistochemistry. The METABRIC BC cohort (n=1980) was evaluated for MYC mRNA expression and a systems biology approach utilised to identify genes associated with MYC in the different BC molecular subtypes. RESULTS: High MYC and c-MYC expression was significantly associated with poor prognostic factors, including grade and basal-like BCs. In luminal A tumours, c-MYC was associated with ATM (P=0.005), Cyclin B1 (P=0.002), PIK3CA (P=0.009) and Ki67 (P<0.001). In contrast, in basal-like tumours, c-MYC showed positive association with Cyclin E (P=0.003) and p16 (P=0.042) expression only. c-MYC was an independent predictor of a shorter distant metastases-free survival in luminal A LN+ tumours treated with endocrine therapy (ET; P=0.013). In luminal tumours treated with ET, MYC mRNA expression was associated with BC-specific survival (P=0.001). In ER-positive tumours, MYC was associated with expression of translational genes while in ER-negative tumours it was associated with upregulation of glucose metabolism genes. CONCLUSIONS: c-MYC function is associated with specific molecular subtypes of BCs and its overexpression confers resistance to ET. The diverse mechanisms of c-MYC function in the different molecular classes of BCs warrants further investigation particularly as potential therapeutic targets. Nature Publishing Group 2016-04-12 2016-03-08 /pmc/articles/PMC4984797/ /pubmed/26954716 http://dx.doi.org/10.1038/bjc.2016.46 Text en Copyright © 2016 Cancer Research UK http://creativecommons.org/licenses/by-nc-sa/4.0/ From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/
spellingShingle Molecular Diagnostics
Green, Andrew R
Aleskandarany, Mohammed A
Agarwal, Devika
Elsheikh, Somaia
Nolan, Christopher C
Diez-Rodriguez, Maria
Macmillan, R Douglas
Ball, Graham R
Caldas, Carlos
Madhusudan, Srinivasan
Ellis, Ian O
Rakha, Emad A
MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours
title MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours
title_full MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours
title_fullStr MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours
title_full_unstemmed MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours
title_short MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours
title_sort myc functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours
topic Molecular Diagnostics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4984797/
https://www.ncbi.nlm.nih.gov/pubmed/26954716
http://dx.doi.org/10.1038/bjc.2016.46
work_keys_str_mv AT greenandrewr mycfunctionsarespecificinbiologicalsubtypesofbreastcancerandconfersresistancetoendocrinetherapyinluminaltumours
AT aleskandaranymohammeda mycfunctionsarespecificinbiologicalsubtypesofbreastcancerandconfersresistancetoendocrinetherapyinluminaltumours
AT agarwaldevika mycfunctionsarespecificinbiologicalsubtypesofbreastcancerandconfersresistancetoendocrinetherapyinluminaltumours
AT elsheikhsomaia mycfunctionsarespecificinbiologicalsubtypesofbreastcancerandconfersresistancetoendocrinetherapyinluminaltumours
AT nolanchristopherc mycfunctionsarespecificinbiologicalsubtypesofbreastcancerandconfersresistancetoendocrinetherapyinluminaltumours
AT diezrodriguezmaria mycfunctionsarespecificinbiologicalsubtypesofbreastcancerandconfersresistancetoendocrinetherapyinluminaltumours
AT macmillanrdouglas mycfunctionsarespecificinbiologicalsubtypesofbreastcancerandconfersresistancetoendocrinetherapyinluminaltumours
AT ballgrahamr mycfunctionsarespecificinbiologicalsubtypesofbreastcancerandconfersresistancetoendocrinetherapyinluminaltumours
AT caldascarlos mycfunctionsarespecificinbiologicalsubtypesofbreastcancerandconfersresistancetoendocrinetherapyinluminaltumours
AT madhusudansrinivasan mycfunctionsarespecificinbiologicalsubtypesofbreastcancerandconfersresistancetoendocrinetherapyinluminaltumours
AT ellisiano mycfunctionsarespecificinbiologicalsubtypesofbreastcancerandconfersresistancetoendocrinetherapyinluminaltumours
AT rakhaemada mycfunctionsarespecificinbiologicalsubtypesofbreastcancerandconfersresistancetoendocrinetherapyinluminaltumours